IncobotulinumtoxinA (Xeomin)

Xeomin (incobotulinumtoxinA) is covered only for adults (≥18) for the four FDA‑approved indications—upper limb spasticity, cervical dystonia, blepharospasm, and chronic sialorrhea—and is not authorized for non‑FDA indications or patients under 18. Approval is for 12 months with indication‑specific maximum doses and minimum intervals: blepharospasm ≤100 U (50 U/eye) no more frequently than every 12 weeks; cervical dystonia ≤120 U no more frequently than every 12 weeks; upper limb spasticity ≤400 U no more frequently than every 12 weeks; chronic sialorrhea ≤100 U (50 U/side) no more frequently than every 16 weeks.

"Upper limb spasticity"

Sign up to see full coverage criteria, indications, and limitations.